



Clinical trial results:

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies

Summary

EudraCT number	2016-001860-12
Trial protocol	DE FR ES IT
Global end of trial date	09 October 2024

Results information

Result version number	v1 (current)
This version publication date	21 August 2025
First version publication date	21 August 2025

Trial information

Trial identification

Sponsor protocol code	CMAK683X2101
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02900651
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	Lichtstrasse 35, Basel, Switzerland, 4056
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 October 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	09 October 2024
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To characterize safety and tolerability and determine the MTD and/or RP2D of MAK683

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 October 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	China: 2
Country: Number of subjects enrolled	France: 33
Country: Number of subjects enrolled	Germany: 13
Country: Number of subjects enrolled	Hong Kong: 10
Country: Number of subjects enrolled	Italy: 19
Country: Number of subjects enrolled	Japan: 11
Country: Number of subjects enrolled	Singapore: 5
Country: Number of subjects enrolled	Spain: 15
Country: Number of subjects enrolled	United States: 24
Worldwide total number of subjects	139
EEA total number of subjects	80

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	89
From 65 to 84 years	49
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled in 16 investigative sites in 10 countries.

Pre-assignment

Screening details:

Screening evaluations had to be completed within 28 days prior to the first dose of study treatment. After screening, the treatment period started on Cycle 1 Day 1.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	10 mg QD

Arm description:

MAK683 10 mg orally once daily

Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MAK683 10 mg orally once daily

Arm title	20 mg QD
------------------	----------

Arm description:

MAK683 20 mg orally once daily

Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MAK683 20 mg orally once daily

Arm title	40 mg QD
------------------	----------

Arm description:

MAK683 40 mg orally once daily

Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MAK683 40 mg orally once daily

Arm title	80 mg QD
------------------	----------

Arm description:

MAK683 80 mg orally once daily

Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MAK683 80 mg orally once daily

Arm title	120 mg QD
------------------	-----------

Arm description:

MAK683 120 mg orally once daily

Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MAK683 120 mg orally once daily

Arm title	160 mg QD
------------------	-----------

Arm description:

MAK683 160 mg orally once daily

Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MAK683 160 mg orally once daily

Arm title	240 mg QD
------------------	-----------

Arm description:

MAK683 240 mg orally once daily

Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MAK683 240 mg orally once daily

Arm title	300 mg QD
------------------	-----------

Arm description:	
MAK683 300 mg orally once daily	
Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
MAK683 300 mg orally once daily	
Arm title	500 mg QD
Arm description:	
MAK683 500 mg orally once daily	
Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
MAK683 500 mg orally once daily	
Arm title	800 mg QD
Arm description:	
MAK683 800 mg orally once daily	
Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
MAK683 800 mg orally once daily	
Arm title	60 mg BID
Arm description:	
MAK683 60 mg orally twice daily	
Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
MAK683 60 mg orally twice daily	
Arm title	80 mg BID
Arm description:	
MAK683 80 mg orally twice daily	
Arm type	Experimental

Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details: MAK683 80 mg orally twice daily	
Arm title	120 mg BID
Arm description: MAK683 120 mg orally twice daily	
Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details: MAK683 120 mg orally twice daily	
Arm title	150 mg BID
Arm description: MAK683 150 mg orally twice daily	
Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details: MAK683 150 mg orally twice daily	
Arm title	300 mg BID
Arm description: MAK683 300 mg orally twice daily	
Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details: MAK683 300 mg orally twice daily	
Arm title	450 mg BID
Arm description: MAK683 450 mg orally twice daily	
Arm type	Experimental
Investigational medicinal product name	MAK683
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:
MAK683 450 mg orally twice daily

Number of subjects in period 1	10 mg QD	20 mg QD	40 mg QD
Started	4	7	3
Completed	0	0	0
Not completed	4	7	3
Physician decision	1	1	-
Death	-	-	-
Progressive Disease	3	5	3
adverse event	-	-	-
Study Terminated by Sponsor	-	-	-
Lost to follow-up	-	-	-
Subject / Guardian Decision	-	1	-

Number of subjects in period 1	80 mg QD	120 mg QD	160 mg QD
Started	8	8	5
Completed	0	0	0
Not completed	8	8	5
Physician decision	-	1	-
Death	-	-	-
Progressive Disease	8	7	4
adverse event	-	-	-
Study Terminated by Sponsor	-	-	-
Lost to follow-up	-	-	1
Subject / Guardian Decision	-	-	-

Number of subjects in period 1	240 mg QD	300 mg QD	500 mg QD
Started	6	4	18
Completed	0	0	0
Not completed	6	4	18
Physician decision	1	-	-
Death	1	-	1
Progressive Disease	4	4	14
adverse event	-	-	1
Study Terminated by Sponsor	-	-	-

Lost to follow-up	-	-	-
Subject / Guardian Decision	-	-	2

Number of subjects in period 1	800 mg QD	60 mg BID	80 mg BID
Started	4	8	11
Completed	0	0	0
Not completed	4	8	11
Physician decision	-	2	1
Death	-	-	1
Progressive Disease	4	4	9
adverse event	-	2	-
Study Terminated by Sponsor	-	-	-
Lost to follow-up	-	-	-
Subject / Guardian Decision	-	-	-

Number of subjects in period 1	120 mg BID	150 mg BID	300 mg BID
Started	11	8	30
Completed	0	0	0
Not completed	11	8	30
Physician decision	1	-	1
Death	-	1	1
Progressive Disease	7	7	22
adverse event	-	-	4
Study Terminated by Sponsor	1	-	-
Lost to follow-up	-	-	-
Subject / Guardian Decision	2	-	2

Number of subjects in period 1	450 mg BID
Started	4
Completed	0
Not completed	4
Physician decision	1
Death	-
Progressive Disease	2
adverse event	1
Study Terminated by Sponsor	-
Lost to follow-up	-
Subject / Guardian Decision	-

Baseline characteristics

Reporting groups

Reporting group title	10 mg QD
Reporting group description: MAK683 10 mg orally once daily	
Reporting group title	20 mg QD
Reporting group description: MAK683 20 mg orally once daily	
Reporting group title	40 mg QD
Reporting group description: MAK683 40 mg orally once daily	
Reporting group title	80 mg QD
Reporting group description: MAK683 80 mg orally once daily	
Reporting group title	120 mg QD
Reporting group description: MAK683 120 mg orally once daily	
Reporting group title	160 mg QD
Reporting group description: MAK683 160 mg orally once daily	
Reporting group title	240 mg QD
Reporting group description: MAK683 240 mg orally once daily	
Reporting group title	300 mg QD
Reporting group description: MAK683 300 mg orally once daily	
Reporting group title	500 mg QD
Reporting group description: MAK683 500 mg orally once daily	
Reporting group title	800 mg QD
Reporting group description: MAK683 800 mg orally once daily	
Reporting group title	60 mg BID
Reporting group description: MAK683 60 mg orally twice daily	
Reporting group title	80 mg BID
Reporting group description: MAK683 80 mg orally twice daily	
Reporting group title	120 mg BID
Reporting group description: MAK683 120 mg orally twice daily	
Reporting group title	150 mg BID
Reporting group description: MAK683 150 mg orally twice daily	
Reporting group title	300 mg BID
Reporting group description: MAK683 300 mg orally twice daily	
Reporting group title	450 mg BID
Reporting group description: MAK683 450 mg orally twice daily	

Reporting group values	10 mg QD	20 mg QD	40 mg QD
Number of subjects	4	7	3
Age Categorical Units: participants			
18 – <65 years	4	4	1
65 – <85 years	0	3	2
≥85 years	0	0	0
Age continuous Units: years			
arithmetic mean	54.0	65.4	60.3
standard deviation	± 6.27	± 8.64	± 19.14
Sex: Female, Male Units: participants			
Female	0	4	1
Male	4	3	2
Race/Ethnicity, Customized Units: Subjects			
Asian	2	3	2
Black	0	0	0
Caucasian	2	2	0
Other	0	0	1
Unknown	0	2	0
Disease classification			
DLBCL - Diffuse large B-cell lymphoma. Solid tumors - including Nasopharyngeal carcinoma, gastric cancer, prostate cancer, ovarian cancer, sarcoma			
Units: Subjects			
DLBCL	1	3	1
Solid tumors	3	4	2

Reporting group values	80 mg QD	120 mg QD	160 mg QD
Number of subjects	8	8	5
Age Categorical Units: participants			
18 – <65 years	3	4	4
65 – <85 years	4	4	1
≥85 years	1	0	0
Age continuous Units: years			
arithmetic mean	66.1	60.4	61.2
standard deviation	± 16.33	± 9.97	± 7.50
Sex: Female, Male Units: participants			
Female	3	4	1
Male	5	4	4
Race/Ethnicity, Customized Units: Subjects			
Asian	3	4	1
Black	0	1	0
Caucasian	4	1	4

Other	1	2	0
Unknown	0	0	0
Disease classification			
DLBCL - Diffuse large B-cell lymphoma. Solid tumors - including Nasopharyngeal carcinoma, gastric cancer, prostate cancer, ovarian cancer, sarcoma			
Units: Subjects			
DLBCL	3	4	0
Solid tumors	5	4	5

Reporting group values	240 mg QD	300 mg QD	500 mg QD
Number of subjects	6	4	18
Age Categorical			
Units: participants			
18 – <65 years	4	1	15
65 – <85 years	2	3	3
≥85 years	0	0	0
Age continuous			
Units: years			
arithmetic mean	59.0	67.0	46.4
standard deviation	± 15.89	± 9.09	± 17.60
Sex: Female, Male			
Units: participants			
Female	2	1	8
Male	4	3	10
Race/Ethnicity, Customized			
Units: Subjects			
Asian	0	0	6
Black	0	0	0
Caucasian	5	1	8
Other	1	3	3
Unknown	0	0	1
Disease classification			
DLBCL - Diffuse large B-cell lymphoma. Solid tumors - including Nasopharyngeal carcinoma, gastric cancer, prostate cancer, ovarian cancer, sarcoma			
Units: Subjects			
DLBCL	2	2	1
Solid tumors	4	2	17

Reporting group values	800 mg QD	60 mg BID	80 mg BID
Number of subjects	4	8	11
Age Categorical			
Units: participants			
18 – <65 years	2	4	6
65 – <85 years	2	4	5
≥85 years	0	0	0
Age continuous			
Units: years			
arithmetic mean	59.0	61.8	63.5
standard deviation	± 13.98	± 16.33	± 9.75
Sex: Female, Male			
Units: participants			
Female	2	1	7

Male	2	7	4
------	---	---	---

Race/Ethnicity, Customized			
Units: Subjects			
Asian	1	1	1
Black	0	1	0
Caucasian	2	1	5
Other	0	5	5
Unknown	1	0	0
Disease classification			
DLBCL - Diffuse large B-cell lymphoma. Solid tumors - including Nasopharyngeal carcinoma, gastric cancer, prostate cancer, ovarian cancer, sarcoma			
Units: Subjects			
DLBCL	1	5	5
Solid tumors	3	3	6

Reporting group values	120 mg BID	150 mg BID	300 mg BID
Number of subjects	11	8	30
Age Categorical			
Units: participants			
18 – <65 years	9	5	22
65 – <85 years	2	3	8
≥85 years	0	0	0
Age continuous			
Units: years			
arithmetic mean	51.6	59.1	54.0
standard deviation	± 14.78	± 13.46	± 15.72
Sex: Female, Male			
Units: participants			
Female	4	1	6
Male	7	7	24
Race/Ethnicity, Customized			
Units: Subjects			
Asian	3	3	5
Black	0	0	1
Caucasian	5	5	15
Other	2	0	3
Unknown	1	0	6
Disease classification			
DLBCL - Diffuse large B-cell lymphoma. Solid tumors - including Nasopharyngeal carcinoma, gastric cancer, prostate cancer, ovarian cancer, sarcoma			
Units: Subjects			
DLBCL	1	1	1
Solid tumors	10	7	29

Reporting group values	450 mg BID	Total	
Number of subjects	4	139	
Age Categorical			
Units: participants			
18 – <65 years	1	89	
65 – <85 years	3	49	

≥85 years	0	1	
-----------	---	---	--

Age continuous Units: years arithmetic mean standard deviation	67.8 ± 9.91	-	
Sex: Female, Male Units: participants			
Female	3	48	
Male	1	91	
Race/Ethnicity, Customized Units: Subjects			
Asian	1	36	
Black	0	3	
Caucasian	2	62	
Other	0	26	
Unknown	1	12	
Disease classification			
DLBCL - Diffuse large B-cell lymphoma. Solid tumors - including Nasopharyngeal carcinoma, gastric cancer, prostate cancer, ovarian cancer, sarcoma			
Units: Subjects			
DLBCL	0	31	
Solid tumors	4	108	

End points

End points reporting groups

Reporting group title	10 mg QD
Reporting group description: MAK683 10 mg orally once daily	
Reporting group title	20 mg QD
Reporting group description: MAK683 20 mg orally once daily	
Reporting group title	40 mg QD
Reporting group description: MAK683 40 mg orally once daily	
Reporting group title	80 mg QD
Reporting group description: MAK683 80 mg orally once daily	
Reporting group title	120 mg QD
Reporting group description: MAK683 120 mg orally once daily	
Reporting group title	160 mg QD
Reporting group description: MAK683 160 mg orally once daily	
Reporting group title	240 mg QD
Reporting group description: MAK683 240 mg orally once daily	
Reporting group title	300 mg QD
Reporting group description: MAK683 300 mg orally once daily	
Reporting group title	500 mg QD
Reporting group description: MAK683 500 mg orally once daily	
Reporting group title	800 mg QD
Reporting group description: MAK683 800 mg orally once daily	
Reporting group title	60 mg BID
Reporting group description: MAK683 60 mg orally twice daily	
Reporting group title	80 mg BID
Reporting group description: MAK683 80 mg orally twice daily	
Reporting group title	120 mg BID
Reporting group description: MAK683 120 mg orally twice daily	
Reporting group title	150 mg BID
Reporting group description: MAK683 150 mg orally twice daily	
Reporting group title	300 mg BID
Reporting group description: MAK683 300 mg orally twice daily	
Reporting group title	450 mg BID

Primary: Incidence of dose limiting toxicities (DLTs)

End point title	Incidence of dose limiting toxicities (DLTs) ^[1]
-----------------	---

End point description:

Number of participants with DLTs. A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 28 days of continuous treatment with MAK683 and meets any of the protocol specified criteria.

End point type	Primary
----------------	---------

End point timeframe:

First cycle of treatment (28 days)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical hypothesis testing was planned for this primary endpoint

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	3	7
Units: participants	0	0	0	0

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	6	4
Units: participants	1	0	1	0

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	4	8	8
Units: participants	1	2	1	2

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	26	4
Units: participants	1	1	2	3

Statistical analyses

Primary: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) ^[2]
-----------------	--

End point description:

Number of participants with AEs and SAEs, including changes in laboratory values, vital signs and ECGs qualifying and reported as AEs.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study treatment until 30 days after last dose up to approximately 5.4 years

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical hypothesis testing was planned for this primary endpoint

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	7	3	8
Units: participants				
AEs	4	7	3	8
Treatment related AEs	4	4	3	3
SAEs	2	3	1	4
Treatment related SAEs	0	0	0	0
Fatal SAEs	0	0	0	0
AEs requiring additional therapy	4	7	2	7

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	5	6	4
Units: participants				
AEs	8	5	6	4
Treatment related AEs	4	2	2	3
SAEs	3	3	4	2
Treatment related SAEs	1	0	0	1
Fatal SAEs	0	0	3	0
AEs requiring additional therapy	6	4	6	3

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	4	8	11
Units: participants				
AEs	18	4	8	11
Treatment related AEs	14	4	8	5
SAEs	6	2	4	8
Treatment related SAEs	1	2	3	2

Fatal SAEs	1	0	1	2
AEs requiring additional therapy	16	4	7	11

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	8	30	4
Units: participants				
AEs	11	8	29	4
Treatment related AEs	9	7	22	4
SAEs	6	2	15	3
Treatment related SAEs	2	1	3	3
Fatal SAEs	0	1	1	1
AEs requiring additional therapy	10	7	25	4

Statistical analyses

No statistical analyses for this end point

Primary: Incidence of dose interruptions and dose reductions

End point title	Incidence of dose interruptions and dose reductions ^[3]
-----------------	--

End point description:

Tolerability measured by the number of subjects who have interruptions or reductions of study treatment

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study treatment until last dose up to approximately 5.3 years (average 57 days)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical hypothesis testing was planned for this primary endpoint

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	7	3	8
Units: participants				
at least one dose reduction or interruption	2	3	1	6
at least one dose reduction	0	0	0	0
at least one dose interruption	2	3	1	6

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	5	6	4
Units: participants				

at least one dose reduction or interruption	4	3	3	3
at least one dose reduction	1	0	1	1
at least one dose interruption	4	3	3	3

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	4	8	11
Units: participants				
at least one dose reduction or interruption	12	4	7	10
at least one dose reduction	3	3	1	1
at least one dose interruption	12	4	7	10

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	8	30	4
Units: participants				
at least one dose reduction or interruption	6	4	19	4
at least one dose reduction	2	2	6	1
at least one dose interruption	5	4	19	4

Statistical analyses

No statistical analyses for this end point

Primary: Dose intensity

End point title	Dose intensity ^[4]
-----------------	-------------------------------

End point description:

Tolerability was measured by the dose of study drug. Dose intensity is defined as the ratio of actual dose received and actual duration of exposure.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study treatment until last dose up to approximately 5.3 years (average 57 days)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical hypothesis testing was planned for this primary endpoint

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	7	3	8
Units: mg/day				
arithmetic mean (standard deviation)	9.9 (± 0.12)	21.1 (± 3.01)	39.9 (± 0.16)	76.1 (± 7.61)

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	5	6	4
Units: mg/day				
arithmetic mean (standard deviation)	106.7 (± 23.10)	154.8 (± 11.58)	223.2 (± 35.79)	269.4 (± 53.05)

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	4	8	11
Units: mg/day				
arithmetic mean (standard deviation)	442.5 (± 99.40)	485.1 (± 180.32)	107.6 (± 17.42)	150.0 (± 25.94)

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	8	30	4
Units: mg/day				
arithmetic mean (standard deviation)	224.5 (± 44.96)	278.4 (± 35.20)	523.4 (± 121.93)	723.3 (± 213.85)

Statistical analyses

No statistical analyses for this end point

Primary: Relative Dose intensity

End point title	Relative Dose intensity ^[5]
End point description:	
Tolerability was measured by the dose of study drug. Relative dose intensity is defined as the ratio of dose intensity to planned dose intensity multiplied by 100.	
End point type	Primary
End point timeframe:	
From first dose of study treatment until last dose up to approximately 5.3 years (average 57 days)	

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical hypothesis testing was planned for this primary endpoint

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	7	3	8
Units: percentage of planned dose intensity				
median (full range (min-max))	100.0 (98 to 100)	100.0 (100 to 140)	100.0 (99 to 100)	100.0 (78 to 104)

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	5	6	4
Units: percentage of planned dose intensity				
median (full range (min-max))	100.0 (46 to 100)	100.0 (84 to 100)	100.0 (63 to 100)	97.9 (63 to 100)

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	4	8	11
Units: percentage of planned dose intensity				
median (full range (min-max))	99.7 (31 to 100)	62.7 (34 to 83)	96.6 (58 to 100)	98.5 (45 to 100)

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	8	30	4
Units: percentage of planned dose intensity				
median (full range (min-max))	100.0 (38 to 103)	99.4 (73 to 100)	100.0 (31 to 100)	84.7 (52 to 100)

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Response Rate (ORR) - DLBCL

End point title	Overall Response Rate (ORR) - DLBCL
-----------------	-------------------------------------

End point description:

Overall response rate (ORR) is the proportion of patients with a best overall response of CR or PR.

Efficacy was based on local investigator assessment, as defined in Cheson 2014.

End point type	Secondary
End point timeframe:	
From first dose of study treatment until 30 days after last dose up to approximately 5.4 years	

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	3	1	3
Units: Percentage of participants				
number (confidence interval 90%)	0.0 (0.0 to 95.0)	33.3 (1.7 to 86.5)	0.0 (0.0 to 95.0)	0.0 (0.0 to 63.2)

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	0 ^[6]	2	2
Units: Percentage of participants				
number (confidence interval 90%)	0.0 (0.0 to 52.7)	(to)	0.0 (0.0 to 77.6)	0.0 (0.0 to 77.6)

Notes:

[6] - No participants in this arm were analyzed for this endpoint

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	5	5
Units: Percentage of participants				
number (confidence interval 90%)	0.0 (0.0 to 95.0)	0.0 (0.0 to 95.0)	40.0 (7.6 to 81.1)	20.0 (1.0 to 65.7)

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	0 ^[7]
Units: Percentage of participants				
number (confidence interval 90%)	0.0 (0.0 to 95.0)	0.0 (0.0 to 95.0)	0.0 (0.0 to 95.0)	(to)

Notes:

[7] - No participants in this arm were analyzed for this endpoint

Statistical analyses

Secondary: Overall Response Rate (ORR) - SOLID TUMORS

End point title	Overall Response Rate (ORR) - SOLID TUMORS
-----------------	--

End point description:

Overall response rate (ORR) is the proportion of patients with a best overall response of CR or PR.

Efficacy was based on based on local investigator assessment, as defined in Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study treatment until 30 days after last dose up to approximately 5.4 years
--

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	2	5
Units: Percentage of participants				
number (confidence interval 90%)	0 (0.0 to 63.2)	0 (0.0 to 52.7)	0 (0.0 to 77.6)	0 (0.0 to 45.1)

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	4	2
Units: Percentage of participants				
number (confidence interval 90%)	0 (0.0 to 52.7)	0 (0.0 to 45.1)	0 (0.0 to 52.7)	0 (0.0 to 77.6)

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	17	3	3	6
Units: Percentage of participants				
number (confidence interval 90%)	5.9 (0.3 to 25.0)	0 (0.0 to 63.2)	0 (0.0 to 63.2)	0 (0.0 to 39.3)

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	7	29	4
Units: Percentage of participants				
number (confidence interval 90%)	20.0 (3.7 to 50.7)	0 (0.0 to 34.8)	0 (0.0 to 9.8)	0 (0.0 to 52.7)

Statistical analyses

No statistical analyses for this end point

Secondary: Best Overall Response (BOR) - DLBCL

End point title	Best Overall Response (BOR) - DLBCL
-----------------	-------------------------------------

End point description:

The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence.

Efficacy was based on local investigator assessment, as defined in Cheson 2014.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study treatment until 30 days after last dose up to approximately 5.4 years

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	3	1	3
Units: participants				
Complete Response (CR)	0	0	0	0
Partial Response (PR)	0	1	0	0
Stable Disease (SD)	0	0	1	0
Progressive Disease (PD)	1	2	0	2
Unknown (UNK)	0	0	0	1

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	0 ^[8]	2	2
Units: participants				
Complete Response (CR)	0		0	0
Partial Response (PR)	0		0	0
Stable Disease (SD)	1		0	0
Progressive Disease (PD)	2		2	2
Unknown (UNK)	1		0	0

Notes:

[8] - No participants in this arm were analyzed for this endpoint

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
------------------	-----------	-----------	-----------	-----------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	5	5
Units: participants				
Complete Response (CR)	0	0	2	0
Partial Response (PR)	0	0	0	1
Stable Disease (SD)	0	0	1	0
Progressive Disease (PD)	1	1	1	3
Unknown (UNK)	0	0	1	1

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	0 ^[9]
Units: participants				
Complete Response (CR)	0	0	0	
Partial Response (PR)	0	0	0	
Stable Disease (SD)	0	1	1	
Progressive Disease (PD)	1	0	0	
Unknown (UNK)	0	0	0	

Notes:

[9] - No participants in this arm were analyzed for this endpoint

Statistical analyses

No statistical analyses for this end point

Secondary: Best Overall Response (BOR) - SOLID TUMORS

End point title	Best Overall Response (BOR) - SOLID TUMORS
-----------------	--

End point description:

The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence.

Efficacy was based on based on local investigator assessment, as defined in Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study treatment until 30 days after last dose up to approximately 5.4 years

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	2	5
Units: participants				
Partial Response (PR)	0	0	0	0
Stable Disease (SD)	0	1	1	3
Progressive Disease (PD)	1	2	1	1
Unknown (UNK)	2	1	0	1

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	4	2
Units: participants				
Partial Response (PR)	0	0	0	0
Stable Disease (SD)	0	1	1	0
Progressive Disease (PD)	4	3	2	2
Unknown (UNK)	0	1	1	0

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	17	3	3	6
Units: participants				
Partial Response (PR)	1	0	0	0
Stable Disease (SD)	9	1	3	1
Progressive Disease (PD)	4	2	0	2
Unknown (UNK)	3	0	0	3

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	7	29	4
Units: participants				
Partial Response (PR)	2	0	0	0
Stable Disease (SD)	2	5	10	1
Progressive Disease (PD)	5	2	16	1
Unknown (UNK)	1	0	3	2

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of overall response (DOR) - DLBCL

End point title	Duration of overall response (DOR) - DLBCL
End point description:	
The time between the date of first documented response (CR or PR) and the date of first documented progression or death. Duration of response was to be estimated using the Kaplan-Meier method.	
Due to EudraCT system limitations, data fields in the table cannot contain letters (eg. NA indicating 'not applicable'). Therefore, not applicable values are indicated as '999'.	
End point type	Secondary

End point timeframe:

From first time of CR/PR to date of death, treatment failure or relapse, up to approximately 5.4 years.

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[10]	1 ^[11]	0 ^[12]	0 ^[13]
Units: months				
median (confidence interval 90%)	(to)	3.7 (-999 to 999)	(to)	(to)

Notes:

[10] - No participants with CR or PR in this arm

[11] - NA: Not estimable due to insufficient number of participants with events

[12] - No participants with CR or PR in this arm

[13] - No participants with CR or PR in this arm

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[14]	0 ^[15]	0 ^[16]	0 ^[17]
Units: months				
median (confidence interval 90%)	(to)	(to)	(to)	(to)

Notes:

[14] - No participants with CR or PR in this arm

[15] - No participants with CR or PR in this arm

[16] - No participants with CR or PR in this arm

[17] - No participants with CR or PR in this arm

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[18]	0 ^[19]	2 ^[20]	1 ^[21]
Units: months				
median (confidence interval 90%)	(to)	(to)	999 (999 to 999)	3.1 (-999 to 999)

Notes:

[18] - No participants with CR or PR in this arm

[19] - No participants with CR or PR in this arm

[20] - NA: Not estimable due to insufficient number of participants with events

[21] - NA: Not estimable due to insufficient number of participants with events

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[22]	0 ^[23]	0 ^[24]	0 ^[25]
Units: months				
median (confidence interval 90%)	(to)	(to)	(to)	(to)

Notes:

[22] - No participants with CR or PR in this arm

[23] - No participants with CR or PR in this arm

[24] - No participants with CR or PR in this arm

[25] - No participants with CR or PR in this arm

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of overall response (DOR) - SOLID TUMORS

End point title	Duration of overall response (DOR) - SOLID TUMORS
-----------------	---

End point description:

The time between the date of first documented response (CR or PR) and the date of first documented progression or death. Duration of response was to be estimated using the Kaplan-Meier method. Due to EudraCT system limitations, data fields in the table cannot contain letters (eg. NA indicating 'not applicable'). Therefore, not applicable values are indicated as '999'.

End point type	Secondary
----------------	-----------

End point timeframe:

From first time of CR/PR to date of death, treatment failure or relapse, up to approximately 5.4 years.

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[26]	0 ^[27]	0 ^[28]	0 ^[29]
Units: months				
median (confidence interval 90%)	(to)	(to)	(to)	(to)

Notes:

[26] - No participants in this arm were analyzed for this endpoint

[27] - No participants in this arm were analyzed for this endpoint

[28] - No participants in this arm were analyzed for this endpoint

[29] - No participants in this arm were analyzed for this endpoint

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[30]	0 ^[31]	0 ^[32]	0 ^[33]
Units: months				
median (confidence interval 90%)	(to)	(to)	(to)	(to)

Notes:

[30] - No participants in this arm were analyzed for this endpoint

[31] - No participants in this arm were analyzed for this endpoint

[32] - No participants in this arm were analyzed for this endpoint

[33] - No participants in this arm were analyzed for this endpoint

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[34]	0 ^[35]	0 ^[36]	0 ^[37]
Units: months				
median (confidence interval 90%)	28.5 (-999 to 999)	(to)	(to)	(to)

Notes:

[34] - NA: Not estimable due to insufficient number of participants with events

[35] - No participants in this arm were analyzed for this endpoint

[36] - No participants in this arm were analyzed for this endpoint

[37] - No participants in this arm were analyzed for this endpoint

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2 ^[38]	0 ^[39]	0 ^[40]	0 ^[41]
Units: months				
median (confidence interval 90%)	999 (999 to 999)	(to)	(to)	(to)

Notes:

[38] - NA: Not estimable due to insufficient number of participants with events

[39] - No participants in this arm were analyzed for this endpoint

[40] - No participants in this arm were analyzed for this endpoint

[41] - No participants in this arm were analyzed for this endpoint

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free survival (PFS) - DLBCL

End point title	Progression-free survival (PFS) - DLBCL
-----------------	---

End point description:

Progression-free survival (PFS) is defined as the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause.

Due to EudraCT system limitations, data fields in the table cannot contain letters (eg. NA indicating 'not applicable'). Therefore, not applicable values are indicated as '999'.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study treatment to date of death, treatment failure or relapse, up to approximately 5.4 years

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[42]	3 ^[43]	1 ^[44]	3 ^[45]
Units: months				
median (confidence interval 90%)	2.4 (-999 to 999)	1.1 (1.0 to 999)	8.4 (-999 to 999)	0.9 (0.8 to 999)

Notes:

[42] - NA: Not estimable due to insufficient number of participants with events

[43] - NA: Not estimable due to insufficient number of participants with events

[44] - NA: Not estimable due to insufficient number of participants with events

[45] - NA: Not estimable due to insufficient number of participants with events

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4 ^[46]	0 ^[47]	2 ^[48]	2 ^[49]
Units: months				
median (confidence interval 90%)	1.8 (1.8 to 999)	(to)	2.0 (1.8 to 999)	1.9 (1.8 to 999)

Notes:

[46] - NA: Not estimable due to insufficient number of participants with events

[47] - No participants in this arm were analyzed for this endpoint

[48] - NA: Not estimable due to insufficient number of participants with events

[49] - NA: Not estimable due to insufficient number of participants with events

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[50]	1 ^[51]	5 ^[52]	5 ^[53]
Units: months				
median (confidence interval 90%)	0.9 (-999 to 999)	2.8 (-999 to 999)	7.5 (1.1 to 999)	1.1 (0.6 to 999)

Notes:

[50] - NA: Not estimable due to insufficient number of participants with events

[51] - NA: Not estimable due to insufficient number of participants with events

[52] - NA: Not estimable due to insufficient number of participants with events

[53] - NA: Not estimable due to insufficient number of participants with events

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1 ^[54]	1 ^[55]	1 ^[56]	0 ^[57]
Units: months				
median (confidence interval 90%)	0.9 (-999 to 999)	5.5 (-999 to 999)	4.1 (-999 to 999)	(to)

Notes:

[54] - NA: Not estimable due to insufficient number of participants with events

[55] - NA: Not estimable due to insufficient number of participants with events

[56] - NA: Not estimable due to insufficient number of participants with events

[57] - No participants in this arm were analyzed for this endpoint

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free survival (PFS) - SOLID TUMORS

End point title	Progression-free survival (PFS) - SOLID TUMORS
-----------------	--

End point description:

Progression-free survival (PFS) is defined as the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause.

Due to EudraCT system limitations, data fields in the table cannot contain letters (eg. NA indicating 'not applicable'). Therefore, not applicable values are indicated as '999'.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study treatment to date of death, treatment failure or relapse, up to approximately 5.4 years

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3 ^[58]	4 ^[59]	2 ^[60]	5 ^[61]
Units: months				
median (confidence interval 90%)	1.6 (1.6 to 999)	1.8 (1.7 to 999)	2.7 (1.9 to 999)	3.9 (1.2 to 999)

Notes:

[58] - NA: Not estimable due to insufficient number of participants with events

[59] - NA: Not estimable due to insufficient number of participants with events

[60] - NA: Not estimable due to insufficient number of participants with events

[61] - NA: Not estimable due to insufficient number of participants with events

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4 ^[62]	5 ^[63]	4 ^[64]	2 ^[65]
Units: months				
median (confidence interval 90%)	1.7 (1.7 to 999)	1.9 (1.8 to 999)	1.1 (1.0 to 999)	1.8 (1.7 to 999)

Notes:

[62] - NA: Not estimable due to insufficient number of participants with events

[63] - NA: Not estimable due to insufficient number of participants with events

[64] - NA: Not estimable due to insufficient number of participants with events

[65] - NA: Not estimable due to insufficient number of participants with events

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	17	3 ^[66]	3 ^[67]	6 ^[68]
Units: months				
median (confidence interval 90%)	3.6 (1.8 to 7.5)	2.0 (1.8 to 999)	10.5 (7.4 to 999)	1.8 (0.2 to 999)

Notes:

[66] - NA: Not estimable due to insufficient number of participants with events

[67] - NA: Not estimable due to insufficient number of participants with events

[68] - NA: Not estimable due to insufficient number of participants with events

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10 ^[69]	7	29	4 ^[70]
Units: months				
median (confidence interval 90%)	1.6 (0.8 to 999)	3.7 (1.0 to 5.6)	1.9 (1.7 to 2.1)	1.7 (1.6 to 999)

Notes:

[69] - NA: Not estimable due to insufficient number of participants with events

[70] - NA: Not estimable due to insufficient number of participants with events

Statistical analyses

No statistical analyses for this end point

Secondary: Peak Plasma Concentration (C_{max}) of MAK683

End point title	Peak Plasma Concentration (C _{max}) of MAK683
End point description:	
The maximum (peak) observed plasma, drug concentration after study drug administration (mass x volume ⁻¹). Due to EudraCT system limitations, data fields in the table cannot contain letters (eg. NA indicating 'not applicable'). Therefore, not applicable values are indicated as '999'.	
End point type	Secondary

End point timeframe:

Cycle 1 day 1 and day 8 and Cycle 2 day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose. 24 hour

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	7	3	8
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	70.9 (± 43.30)	176 (± 108.00)	337 (± 157.00)	871 (± 548.00)
Cycle 1 day 8 n= 4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	67.4 (± 43.90)	143 (± 87.60)	333 (± 118.00)	743 (± 516.00)
Cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	71.4 (± 12.40)	175 (± 54.30)	239 (± 147.00)	788 (± 355.00)

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	5	6	4
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	659 (± 573.00)	1380 (± 792.00)	1920 (± 1690.00)	3310 (± 949.00)
Cycle 1 day 8 n= 4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	943 (± 643.00)	1560 (± 1330.00)	1150 (± 861.00)	3450 (± 1170.00)
Cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	995 (± 558.00)	1620 (± 1150.00)	1530 (± 755.00)	2080 (± 1150.0)

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	4	7	9
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	3330 (± 2020.00)	9470 (± 4250.00)	518 (± 221.00)	496 (± 411.00)
Cycle 1 day 8 n= 4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	3120 (± 1940.00)	10500 (± 3820.00)	502 (± 224.00)	622 (± 402.00)
Cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	2380 (± 1810.00)	4890 (± 127.00)	669 (± 220.00)	691 (± 324.00)

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	8	26	3 ^[71]
Units: ng/mL				
arithmetic mean (standard deviation)				

Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	973 (± 645.00)	823 (± 514.00)	1490 (± 1620)	2880 (± 2280.00)
Cycle 1 day 8 n= 4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	999 (± 579.00)	1260 (± 851.00)	2200 (± 1900.00)	3400 (± 3220.00)
Cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	575 (± 569.00)	1340 (± 807.00)	1510 (± 1380.00)	999 (± 999)

Notes:

[71] - NA: Not applicable due to 0 participants analyzed on Cycle 2 day 1

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration (AUClast) Time Curve of MAK683

End point title	Area Under the Plasma Concentration (AUClast) Time Curve of MAK683
-----------------	--

End point description:

The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1).

Due to EudraCT system limitations, data fields in the table cannot contain letters (eg. NA indicating 'not applicable'). Therefore, not applicable values are indicated as '999'.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 day 1 and day 8 and Cycle 2 day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose. 24 hour post-dose is collected for QD arms and a 12hour post-dose for BID arms.

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	7	3	8
Units: hours*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	326 (± 160.00)	646 (± 254.00)	2000 (± 977.00)	3620 (± 1610.00)
Cycle 1 day 8 n=4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	362 (± 79.10)	583 (± 269.00)	2130 (± 1200.00)	4700 (± 2260.00)
Cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	480 (± 102.00)	796 (± 188.00)	1560 (± 894.00)	3900 (± 1190.00)

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	5	6	4
Units: hours*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	3700 (± 2670.00)	5570 (± 2340.00)	10100 (± 7080.00)	13300 (± 5720.00)
Cycle 1 day 8 n=4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	4390 (± 2160.00)	6330 (± 3170.00)	8440 (± 7270.00)	19600 (± 10200.00)
Cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	5590 (± 3360.00)	7960 (± 4530.00)	9870 (± 3680.00)	12300 (± 6900.00)

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	4	7	9
Units: hours*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	16300 (± 9570.00)	52300 (± 33700.00)	1520 (± 651.00)	1650 (± 1310.00)
Cycle 1 day 8 n=4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	19400 (± 11800.00)	77400 (± 43700.00)	1830 (± 76700)	2760 (± 2010.00)
Cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	14800 (± 10500.00)	20200 (± 4690.00)	2180 (± 841.00)	2370 (± 1070.00)

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	8	26	3 ^[72]
Units: hours*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	3040 (± 1990.00)	2630 (± 1760.00)	4340 (± 4670.00)	8720 (± 7370.00)
Cycle 1 day 8 n=4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	4360 (± 2210.00)	4080 (± 1910.00)	9700 (± 8860.00)	20400 (± 20800.00)
Cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	2130 (± 1850.00)	3950 (± 1920.00)	5200 (± 4050.00)	999 (± 999)

Notes:

[72] - NA: Not applicable due to 0 participants analyzed on Cycle 2 day 1

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration (AUCinf) Time Curve of MAK683

End point title	Area Under the Plasma Concentration (AUCinf) Time Curve of MAK683
-----------------	---

End point description:

The AUC from time zero to infinity (mass x time x volume⁻¹).

Due to EudraCT system limitations, data fields in the table cannot contain letters (eg. NA indicating 'not applicable'). Therefore, not applicable values are indicated as '999'.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 day 1 and day 8 and Cycle 2 day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose. 24 hour post-dose is collected for QD arms and a 12hour post-dose for BID arms.

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	3	8
Units: hours*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=3,6,3,8,7,5,5,4,14,4,4,6,7,4,12,2	417 (± 79.60)	733 (± 184.00)	2060 (± 1030.00)	3700 (± 1670.00)
Cycle 1 day 8 n= 3,6,3,5,6,3,3,3,13,4,4,7,6,8,14,2	398 (± 62.00)	684 (± 144.00)	2200 (± 1260.00)	4620 (± 2160.00)
cycle 2 day 1 n=2,4,3,5,6,4,3,4,9,2,2,4,1,1,7,0	430 (± 24.80)	721 (± 14.10)	1640 (± 909.00)	4020 (± 1310.00)

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	5	6	4
Units: hours*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=3,6,3,8,7,5,5,4,14,4,4,6,7,4,12,2	3280 (± 2450.00)	5750 (± 2210.00)	10700 (± 7940.00)	13600 (± 6030.00)
Cycle 1 day 8 n= 3,6,3,5,6,3,3,3,13,4,4,7,6,8,14,2	4660 (± 2350.00)	6030 (± 3720.00)	7740 (± 6420.00)	20600 (± 11700.00)
cycle 2 day 1 n=2,4,3,5,6,4,3,4,9,2,2,4,1,1,7,0	5710 (± 3490.00)	8090 (± 4520.00)	10200 (± 4720.00)	12600 (± 7150.00)

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14	4	6	7
Units: hours*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=3,6,3,8,7,5,5,4,14,4,4,6,7,4,12,2	16500 (± 9980.00)	53800 (± 35900.00)	1820 (± 708.00)	2330 (± 1670.00)
Cycle 1 day 8 n= 3,6,3,5,6,3,3,3,13,4,4,7,6,8,14,2	19900 (± 12100.00)	81000 (± 47000.00)	2290 (± 569.00)	2500 (± 1190.00)
cycle 2 day 1 n=2,4,3,5,6,4,3,4,9,2,2,4,1,1,7,0	15100 (± 10800.00)	20900 (± 5250.00)	1330 (± 86.40)	3110 (± 923.00)

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7 ^[73]	8 ^[74]	14	2 ^[75]
Units: hours*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 day 1 n=3,6,3,8,7,5,5,4,14,4,4,6,7,4,12,2	4330 (± 2310.00)	3760 (± 1700.00)	6910 (± 4040.00)	15100 (± 4220.00)
Cycle 1 day 8 n= 3,6,3,5,6,3,3,3,13,4,4,7,6,8,14,2	4390 (± 2900.00)	4440 (± 2040.00)	10800 (± 4380.00)	35100 (± 21000.00)

cycle 2 day 1 n=2,4,3,5,6,4,3,4,9,2,2,4,1,1,7,0	3650 (± 999)	4560 (± 999)	7880 (± 5090.00)	999 (± 999)
--	--------------	--------------	------------------	-------------

Notes:

[73] - NA: Not estimable due to insufficient number of participants

[74] - NA: Not estimable due to insufficient number of participants

[75] - NA: Not applicable due to 0 participants analyzed on Cycle 2 day 1

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Peak Plasma Concentration (Tmax) of MAK683

End point title	Time to Peak Plasma Concentration (Tmax) of MAK683
-----------------	--

End point description:

The time to reach maximum (peak) plasma drug concentration after study drug administration (time). Due to EudraCT system limitations, data fields in the table cannot contain letters (eg. NA indicating 'not applicable'). Therefore, not applicable values are indicated as '999'.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 day 1 and day 8 and Cycle 2 day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose. 24 hour post-dose is collected for QD arms and a 12hour post-dose for BID arms.

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	7	3	8
Units: hours				
median (full range (min-max))				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	1.07 (0.917 to 7.03)	2.08 (0.5 to 3)	1.05 (0.983 to 3)	1 (0.5 to 3.03)
Cycle 1 day 8 n= 4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	1.6 (1 to 5.5)	1.08 (0.467 to 2.02)	2 (2 to 2.03)	0.975 (0.5 to 7)
cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	2.15 (2 to 5.45)	1 (0.5 to 7.77)	2.97 (1 to 3)	1.03 (0.5 to 3.03)

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	5	6	4
Units: hours				
median (full range (min-max))				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	1.05 (0.567 to 8.05)	1 (0.583 to 2)	3.23 (1 to 6.17)	1 (0.567 to 1.02)
Cycle 1 day 8 n= 4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	1 (0.583 to 5.97)	1.08 (0.583 to 1.93)	4.08 (0.5 to 6.08)	2 (0.5 to 2.15)
cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	2.03 (0.417 to 3)	1.08 (1.08 to 2)	2 (0.583 to 3.93)	2.07 (1.03 to 3.92)

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	4	7	9
Units: hours				
median (full range (min-max))				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	2 (0.983 to 3.85)	1.52 (0.817 to 2.17)	1 (0.617 to 4)	1.08 (0.5 to 4)
Cycle 1 day 8 n= 4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	2.13 (0.75 to 4.05)	1.33 (0.95 to 1.98)	1.05 (0.5 to 2)	2 (0.517 to 3.5)
cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	1.98 (0.833 to 3.83)	0.867 (0.583 to 1.15)	1 (0 to 2.03)	1.18 (0.833 to 4)

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	8	26	3 ^[76]
Units: hours				
median (full range (min-max))				
Cycle 1 day 1 n=4,7,3,8,8,5,6,4,15,4,7,9,10,5,25,3	1.08 (0.5 to 2.03)	1.82 (0.9 to 2.08)	2.08 (0.5 to 8.02)	1.17 (0.417 to 8.02)
Cycle 1 day 8 n= 4,7,3,8,7,4,5,3,13,4,5,9,9,8,26,3	1.12 (0 to 6)	1.05 (0.4 to 2.8)	1.99 (0 to 7.92)	1.08 (0.5 to 2.92)
cycle 2 day 1 n= 3,5,3,5,6,4,4,4,9,2,6,5,5,6,20,0	1.95 (1.12 to 2.98)	1.07 (0.4 to 2)	2.08 (0 to 6.05)	999 (999 to 999)

Notes:

[76] - NA: Not applicable due to 0 participants analyzed on Cycle 2 day 1

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline H3K27 tri methylation level in PBMC

End point title	Change from baseline H3K27 tri methylation level in PBMC ^[77]
-----------------	--

End point description:

Best percent change from baseline for H3K12 trimethylation in peripheral blood mononuclear cell (PBMC). Where "Best percent change from baseline" is defined as maximum reduction from baseline at any on-treatment time point. Different cell populations were evaluated.

Due to EudraCT system limitations, data fields in the table cannot contain letters (eg. NA indicating 'not applicable'). Therefore, not applicable values are indicated as '999'.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 1,8 and 15, Cycle 2 Day 1, Cycle 3 Day 1

Notes:

[77] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Change in H3K27 trimethylation in PBMC was only assessed in subsets of participants treated with ≥ 500 mg QD and the entire BID dose range of MAK683 evaluated.

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	3 ^[78]	2 ^[79]	3 ^[80]
Units: Percent change in H3K27 trimethylation				
arithmetic mean (standard deviation)				
CD19+ population n= 7,2,,2,1,3,3,11,1	-57.6 (± 29.36)	-58 (± 22.27)	-88.6 (± 3.68)	-38 (± 999)
CD3+ population n= 5,1,1,1,3,4,12,0	-61.5 (± 37.42)	-34.4 (± 999)	-31.9 (± 999)	-88.7 (± 999)
HLADR+CD14+ population n=8,3,2,3,4,6,16,2	-87 (± 9.35)	-80.9 (± 27.22)	-78.3 (± 2.19)	-89.8 (± 16.43)

Notes:

[78] - NA: Not applicable due to single participant analyzed for CD3+

[79] - NA: Not applicable due to single participant analyzed for CD3+

[80] - NA: Not applicable due to single participant analyzed for CD3+

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	6	16	2 ^[81]
Units: Percent change in H3K27 trimethylation				
arithmetic mean (standard deviation)				
CD19+ population n= 7,2,,2,1,3,3,11,1	-63.9 (± 23.33)	-66.1 (± 22.84)	-46.1 (± 25.08)	-16.3 (± 999)
CD3+ population n= 5,1,1,1,3,4,12,0	-44 (± 46.46)	-26.8 (± 24.28)	-50.4 (± 28.50)	999 (± 999)
HLADR+CD14+ population n=8,3,2,3,4,6,16,2	-84.4 (± 10.67)	-77.7 (± 24.19)	-79.7 (± 17.69)	-84.3 (± 13.15)

Notes:

[81] - NA: Not applicable due to single participant analyzed for CD19+ and 0 participants for CD3+

Statistical analyses

No statistical analyses for this end point

Post-hoc: All collected deaths

End point title	All collected deaths
-----------------	----------------------

End point description:

On-treatment deaths were collected from first dose of study treatment to 30 days after last dose.

Post- treatment and disease progression FU deaths were collected from 31 days after last dose until end of study.

All deaths refer to the sum of pre-treatment deaths, on-treatment, post-treatment safety FU deaths, and disease progression FU deaths.

End point type	Post-hoc
----------------	----------

End point timeframe:

On-treatment deaths: up to approximately 5.4 years. Post-treatment safety FU and disease progression FU deaths: up to 5.4 years

End point values	10 mg QD	20 mg QD	40 mg QD	80 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	7	3	8
Units: participants				
On treatment deaths	0	1	0	0
Post-treatment death	3	1	0	1
Total deaths	3	2	0	1

End point values	120 mg QD	160 mg QD	240 mg QD	300 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	5	6	4
Units: participants				
On treatment deaths	0	0	3	0
Post-treatment death	2	0	0	1
Total deaths	2	0	3	1

End point values	500 mg QD	800 mg QD	60 mg BID	80 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	4	8	11
Units: participants				
On treatment deaths	1	0	0	3
Post-treatment death	1	0	1	3
Total deaths	2	0	1	6

End point values	120 mg BID	150 mg BID	300 mg BID	450 mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	8	30	4
Units: participants				
On treatment deaths	1	1	2	0
Post-treatment death	2	1	7	2
Total deaths	3	2	9	2

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

On treatment Adverse events and deaths : from first dose of study treatment until 30 days after last treatment up to maximum duration of 5.4 years

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.1
--------------------	------

Reporting groups

Reporting group title	Phase I 40 mg QD fasted
-----------------------	-------------------------

Reporting group description:

Phase I 40 mg QD fasted

Reporting group title	Phase I 20 mg QD fasted
-----------------------	-------------------------

Reporting group description:

Phase I 20 mg QD fasted

Reporting group title	Phase I 10 mg QD fasted
-----------------------	-------------------------

Reporting group description:

Phase I 10 mg QD fasted

Reporting group title	Phase I 240 mg QD fasted
-----------------------	--------------------------

Reporting group description:

Phase I 240 mg QD fasted

Reporting group title	Phase I 450 mg BID fasted
-----------------------	---------------------------

Reporting group description:

Phase I 450 mg BID fasted

Reporting group title	Phase I 500 mg QD fasted
-----------------------	--------------------------

Reporting group description:

Phase I 500 mg QD fasted

Reporting group title	Phase I 800 mg QD fasted
-----------------------	--------------------------

Reporting group description:

Phase I 800 mg QD fasted

Reporting group title	Phase I 60 mg BID fasted
-----------------------	--------------------------

Reporting group description:

Phase I 60 mg BID fasted

Reporting group title	Phase I 80 mg BID fasted
-----------------------	--------------------------

Reporting group description:

Phase I 80 mg BID fasted

Reporting group title	Phase I 120 mg BID fasted
-----------------------	---------------------------

Reporting group description:

Phase I 120 mg BID fasted

Reporting group title	Phase I 150 mg BID fasted
-----------------------	---------------------------

Reporting group description:

Phase I 150 mg BID fasted

Reporting group title	Phase I 300 mg BID fasted
-----------------------	---------------------------

Reporting group description:

Phase I 300 mg BID fasted

Reporting group title	Phase I 160 mg QD fasted
Reporting group description: Phase I 160 mg QD fasted	
Reporting group title	Phase I 120 mg QD fasted
Reporting group description: Phase I 120 mg QD fasted	
Reporting group title	Phase I 80 mg QD fasted
Reporting group description: Phase I 80 mg QD fasted	
Reporting group title	Phase I 300 mg QD fasted
Reporting group description: Phase I 300 mg QD fasted	

Serious adverse events	Phase I 40 mg QD fasted	Phase I 20 mg QD fasted	Phase I 10 mg QD fasted
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 3 (33.33%)	3 / 7 (42.86%)	2 / 4 (50.00%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphangiosis carcinomatosa			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant pleural effusion			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic neoplasm			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour associated fever			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arterial haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Condition aggravated			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Red blood cell morphology abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Clavicle fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular access complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Left ventricular dysfunction			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Bell's palsy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonella bacteraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suspected COVID-19			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase I 240 mg QD fasted	Phase I 450 mg BID fasted	Phase I 500 mg QD fasted
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 6 (66.67%)	3 / 4 (75.00%)	6 / 18 (33.33%)
number of deaths (all causes)	3	0	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphangiosis carcinomatosa			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Malignant pleural effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic neoplasm			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour associated fever			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Vascular disorders			
Arterial haemorrhage			

subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Condition aggravated			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 6 (16.67%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Haemoptysis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Red blood cell morphology abnormal subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Clavicle fracture subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular access complication subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Left ventricular dysfunction subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Bell's palsy subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 6 (16.67%)	2 / 4 (50.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonella bacteraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suspected COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			

Dehydration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase I 800 mg QD fasted	Phase I 60 mg BID fasted	Phase I 80 mg BID fasted
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 4 (50.00%)	4 / 8 (50.00%)	8 / 11 (72.73%)
number of deaths (all causes)	0	0	3
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Lymphangiosis carcinomatosa			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant pleural effusion			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic neoplasm			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour associated fever			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arterial haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Condition aggravated			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Red blood cell morphology abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Clavicle fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular access complication			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Left ventricular dysfunction			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Bell's palsy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			

subjects affected / exposed	1 / 4 (25.00%)	1 / 8 (12.50%)	2 / 11 (18.18%)
occurrences causally related to treatment / all	1 / 1	1 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonella bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			

subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suspected COVID-19			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase I 120 mg BID fasted	Phase I 150 mg BID fasted	Phase I 300 mg BID fasted
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 11 (54.55%)	2 / 8 (25.00%)	15 / 30 (50.00%)
number of deaths (all causes)	1	1	2
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphangiosis carcinomatosa			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant pleural effusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic neoplasm			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour associated fever			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arterial haemorrhage			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Condition aggravated			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Haemoptysis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Red blood cell morphology abnormal subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Clavicle fracture subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular access complication subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Left ventricular dysfunction subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Bell's palsy subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences causally related to treatment / all	1 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Musculoskeletal and connective tissue			

disorders			
Back pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 8 (25.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonella bacteraemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suspected COVID-19			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			

Dehydration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase I 160 mg QD fasted	Phase I 120 mg QD fasted	Phase I 80 mg QD fasted
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 5 (60.00%)	3 / 8 (37.50%)	4 / 8 (50.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphangiosis carcinomatosa			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant pleural effusion			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic neoplasm			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour associated fever			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arterial haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Condition aggravated			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	2 / 8 (25.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Red blood cell morphology abnormal			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Clavicle fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular access complication			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Left ventricular dysfunction			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Bell's palsy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			

subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonella bacteraemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suspected COVID-19			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase I 300 mg QD fasted		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 4 (50.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphangiosis carcinomatosa			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant neoplasm progression			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic neoplasm			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tumour associated fever			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Arterial haemorrhage			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Condition aggravated			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Haemoptysis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutrophil count decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Platelet count decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Red blood cell morphology abnormal subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Clavicle fracture subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular access complication subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Left ventricular dysfunction subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Bell's palsy subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Presyncope subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular accident subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal cord compression			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ascites			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			

subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dysphagia				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ileus				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal obstruction				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nausea				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Obstruction gastric				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal stenosis				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatitis				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small intestinal obstruction				

subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hydronephrosis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue			

disorders				
Back pain				
subjects affected / exposed	1 / 4 (25.00%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bone pain				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
COVID-19				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumocystis jirovecii pneumonia				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia mycoplasmal				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia pneumococcal				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Postoperative wound infection				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Respiratory tract infection				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Salmonella bacteraemia				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Septic shock				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sinusitis				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Staphylococcal bacteraemia				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Suspected COVID-19				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metabolism and nutrition disorders				

Dehydration			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Phase I 40 mg QD fasted	Phase I 20 mg QD fasted	Phase I 10 mg QD fasted
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	6 / 7 (85.71%)	4 / 4 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tumour associated fever			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	1 / 3 (33.33%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Subclavian vein thrombosis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pallor			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Venous thrombosis limb			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Chronic fatigue syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
Asthenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	1 / 3 (33.33%)	2 / 7 (28.57%)	3 / 4 (75.00%)
occurrences (all)	1	2	3
Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
General physical health deterioration			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hyperthermia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
Mucosal inflammation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Supraclavicular fossa pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Swelling face			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Temperature regulation disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Xerosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Amenorrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Penile oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Aspiration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 3 (0.00%)	2 / 7 (28.57%)	1 / 4 (25.00%)
occurrences (all)	0	2	1
Dysphonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Hiccups			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			

subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Pneumonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Lung infiltration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pulmonary tumour thrombotic microangiopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Rhinorrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Depression			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Depressive symptom			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Fear of eating			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood albumin decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Blood creatine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood calcium decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood sodium increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Protein total decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	1 / 3 (33.33%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Hepatic enzyme abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SARS-CoV-2 test negative			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vitamin D decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
White blood cell count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Clavicle fracture			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Eye contusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Post procedural haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Radiation skin injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Transfusion reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vascular access complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Tricuspid valve disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Supraventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Pericardial effusion subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Mitral valve thickening subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Nervous system disorders			
Bell's palsy subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Drooling subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Neuralgia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	1 / 4 (25.00%) 1
Myoclonus subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	1 / 4 (25.00%) 1
Headache subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	1 / 4 (25.00%) 1
Febrile convulsion subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Dysgeusia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Peripheral motor neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Transient ischaemic attack			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vlth nerve paralysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	1 / 3 (33.33%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Anaemia			
subjects affected / exposed	1 / 3 (33.33%)	2 / 7 (28.57%)	1 / 4 (25.00%)
occurrences (all)	2	2	1
Iron deficiency anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Leukopenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Lymphopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
External ear inflammation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Middle ear effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eye oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Glaucoma			

subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Papilloedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Uveitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Retinopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Abdominal rigidity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	2 / 7 (28.57%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
Angular cheilitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Ascites			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	2 / 7 (28.57%)	1 / 4 (25.00%)
occurrences (all)	0	2	1
Dental caries			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dental discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	2 / 7 (28.57%)	1 / 4 (25.00%)
occurrences (all)	0	2	2
Dry mouth			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Gingival bleeding			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Intestinal stenosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ileus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	3 / 7 (42.86%)	1 / 4 (25.00%)
occurrences (all)	0	3	2
Odynophagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tooth loss			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	2 / 7 (28.57%)	2 / 4 (50.00%)
occurrences (all)	0	2	3
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hepatic cytolysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hepatic vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Jaundice			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
Pruritus			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Prurigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin erosion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nocturia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Urine flow decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Renal impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Renal failure			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypopituitarism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	2 / 4 (50.00%)
occurrences (all)	0	0	2
Musculoskeletal chest pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Spinal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Synovitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Temporomandibular pain and dysfunction syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Abdominal infection			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Bronchitis viral			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
COVID-19			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Candida infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Herpes ophthalmic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Influenza subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Oral fungal infection subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Oral viral infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Periodontitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Peritonsillar abscess subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	0 / 4 (0.00%) 0
Pneumocystis jirovecii pneumonia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Septic shock subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	0 / 4 (0.00%) 0

Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Tooth infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Soft tissue infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	0 / 4 (0.00%) 0
Metabolism and nutrition disorders			
Cell death subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	4 / 7 (57.14%) 4	2 / 4 (50.00%) 2
Fluid retention subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 4 (0.00%) 0
Dehydration			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Hyperamylasaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hyperkalaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hypernatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypochloraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Hypoglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 3 (33.33%)	1 / 7 (14.29%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Vitamin D deficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Phase I 240 mg QD fasted	Phase I 450 mg BID fasted	Phase I 500 mg QD fasted
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 6 (100.00%)	4 / 4 (100.00%)	18 / 18 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Tumour associated fever			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Subclavian vein thrombosis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pallor			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Venous thrombosis limb			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chronic fatigue syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Chills			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	2 / 6 (33.33%)	1 / 4 (25.00%)	2 / 18 (11.11%)
occurrences (all)	2	1	2
Early satiety			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	2 / 18 (11.11%)
occurrences (all)	0	1	2
Gait disturbance			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			

subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Hyperthermia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Facial pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Oedema peripheral			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Supraclavicular fossa pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	4 / 18 (22.22%)
occurrences (all)	0	2	4
Peripheral swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Swelling face			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Temperature regulation disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Xerosis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Reproductive system and breast disorders			
Amenorrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pelvic pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Penile oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Aspiration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Cough			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	5 / 18 (27.78%)
occurrences (all)	0	0	5
Dysphonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Nasal congestion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Oropharyngeal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pleural effusion			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Lung infiltration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pulmonary tumour thrombotic microangiopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Respiratory failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Wheezing			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Depression			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Depressive symptom			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Fear of eating			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Insomnia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	3	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood albumin decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Blood bilirubin increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	3
Blood magnesium decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Blood lactate dehydrogenase increased			

subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Blood creatinine increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	2 / 18 (11.11%)
occurrences (all)	2	0	3
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Blood creatine increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood calcium decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Blood phosphorus decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood sodium increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	2 / 18 (11.11%)
occurrences (all)	0	1	2
Protein total decreased			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Platelet count decreased			
subjects affected / exposed	0 / 6 (0.00%)	2 / 4 (50.00%)	1 / 18 (5.56%)
occurrences (all)	0	2	3
Neutrophil count decreased			
subjects affected / exposed	1 / 6 (16.67%)	1 / 4 (25.00%)	3 / 18 (16.67%)
occurrences (all)	2	1	27
Lymphocyte count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	4
Lipase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme abnormal			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
SARS-CoV-2 test negative			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Vitamin D decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	2 / 18 (11.11%)
occurrences (all)	0	1	2
White blood cell count decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	4 / 18 (22.22%)
occurrences (all)	0	1	23
Injury, poisoning and procedural complications			
Clavicle fracture			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Post procedural haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Radiation skin injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Transfusion reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Vascular access complication			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Cardiac disorders			
Tricuspid valve disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0

Supraventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 4 (25.00%) 1	0 / 18 (0.00%) 0
Pericardial effusion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Mitral valve thickening subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Nervous system disorders			
Bell's palsy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 4 (25.00%) 1	0 / 18 (0.00%) 0
Drooling subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Neuralgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Myoclonus subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Febrile convulsion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Dysgeusia			

subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Neuropathy peripheral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	3 / 18 (16.67%)
occurrences (all)	0	0	3
Peripheral motor neuropathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Sciatica			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Presyncope			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Transient ischaemic attack			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vlth nerve paralysis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	1 / 6 (16.67%)	2 / 4 (50.00%)	3 / 18 (16.67%)
occurrences (all)	1	4	3
Anaemia			
subjects affected / exposed	1 / 6 (16.67%)	3 / 4 (75.00%)	6 / 18 (33.33%)
occurrences (all)	1	3	7
Iron deficiency anaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Leukopenia			
subjects affected / exposed	0 / 6 (0.00%)	2 / 4 (50.00%)	0 / 18 (0.00%)
occurrences (all)	0	4	0
Lymphopenia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	3 / 4 (75.00%)	2 / 18 (11.11%)
occurrences (all)	0	5	5
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
External ear inflammation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Middle ear effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Vertigo			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Eye oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Glaucoma			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Papilloedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Uveitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Retinopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Periorbital oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Abdominal rigidity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	2 / 6 (33.33%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	2	0	0
Angular cheilitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Ascites			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	2 / 6 (33.33%)	1 / 4 (25.00%)	4 / 18 (22.22%)
occurrences (all)	2	1	4
Dental caries			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Dental discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	1 / 6 (16.67%)	1 / 4 (25.00%)	4 / 18 (22.22%)
occurrences (all)	1	1	5
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Gingival bleeding			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Intestinal stenosis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Inguinal hernia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Ileus			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	3 / 6 (50.00%)	2 / 4 (50.00%)	8 / 18 (44.44%)
occurrences (all)	4	2	9
Odynophagia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Rectal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Tooth loss			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	2 / 6 (33.33%)	1 / 4 (25.00%)	7 / 18 (38.89%)
occurrences (all)	3	1	7
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hepatic cytolysis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hepatic vein thrombosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Jaundice			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	2 / 18 (11.11%)
occurrences (all)	0	1	2
Dermatitis allergic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Eczema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Night sweats			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Petechiae			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	6 / 18 (33.33%)
occurrences (all)	0	0	8
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Prurigo			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Rash pruritic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin erosion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nocturia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	2
Pollakiuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Urine flow decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Renal impairment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Renal failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypopituitarism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Back pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	4 / 18 (22.22%)
occurrences (all)	1	0	4
Musculoskeletal chest pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Bone pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Spinal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Synovitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Temporomandibular pain and dysfunction syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Abdominal infection			

subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Bronchitis viral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Gingivitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Candida infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Herpes ophthalmic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1

Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Influenza subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Oral fungal infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Oral viral infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Periodontitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	1 / 18 (5.56%) 1
Peritonsillar abscess subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Pneumocystis jirovecii pneumonia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	1 / 18 (5.56%) 1
Pneumonia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	1 / 18 (5.56%) 1
Septic shock subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0

Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	1 / 18 (5.56%) 1
Sinusitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	1 / 18 (5.56%) 1
Tooth infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Soft tissue infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	1 / 18 (5.56%) 1
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	1 / 18 (5.56%) 1
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Metabolism and nutrition disorders			
Cell death subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 3	2 / 4 (50.00%) 2	2 / 18 (11.11%) 2
Fluid retention subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 18 (0.00%) 0
Dehydration			

subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Hyperamylasaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hypercalcaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hyperkalaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypernatraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypochloraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 4 (25.00%)	1 / 18 (5.56%)
occurrences (all)	0	1	2
Hypoglycaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Hypomagnesaemia			

subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Hyponatraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Hypophosphataemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 4 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Vitamin D deficiency			
subjects affected / exposed	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Phase I 800 mg QD fasted	Phase I 60 mg BID fasted	Phase I 80 mg BID fasted
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)	8 / 8 (100.00%)	11 / 11 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Tumour associated fever			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Tumour haemorrhage			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	3 / 11 (27.27%)
occurrences (all)	0	0	3
Vascular disorders			
Flushing			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Hypertension			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Subclavian vein thrombosis			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Pallor			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Venous thrombosis limb			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chronic fatigue syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Asthenia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 8 (25.00%)	2 / 11 (18.18%)
occurrences (all)	0	4	2
Early satiety			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	2 / 4 (50.00%)	1 / 8 (12.50%)	1 / 11 (9.09%)
occurrences (all)	2	1	1
Gait disturbance			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hyperthermia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Face oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	2 / 11 (18.18%)
occurrences (all)	0	0	2
Swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Supraclavicular fossa pain			

subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	3 / 8 (37.50%)	3 / 11 (27.27%)
occurrences (all)	0	6	3
Peripheral swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Swelling face			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Temperature regulation disorder			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Xerosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Amenorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Penile oedema			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Vaginal haemorrhage			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Aspiration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 4 (0.00%)	3 / 8 (37.50%)	0 / 11 (0.00%)
occurrences (all)	0	4	0
Dysphonia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	1	2	0
Haemoptysis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Hiccups			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Pleural effusion			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Pneumonitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Hypoxia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Lung infiltration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Productive cough			
subjects affected / exposed	0 / 4 (0.00%)	2 / 8 (25.00%)	0 / 11 (0.00%)
occurrences (all)	0	3	0
Pulmonary embolism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Pulmonary tumour thrombotic microangiopathy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Wheezing			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Depression			

subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Depressive symptom			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Fear of eating			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	2 / 11 (18.18%)
occurrences (all)	0	0	2
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 4 (25.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Amylase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 4 (25.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	3	1	0
Blood albumin decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Blood bilirubin increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Blood magnesium decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	2 / 4 (50.00%)	0 / 8 (0.00%)	2 / 11 (18.18%)
occurrences (all)	2	0	2
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Blood creatine increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Blood calcium decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus decreased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Blood sodium increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Protein total decreased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	2 / 4 (50.00%)	0 / 8 (0.00%)	3 / 11 (27.27%)
occurrences (all)	4	0	3
Neutrophil count decreased			
subjects affected / exposed	1 / 4 (25.00%)	2 / 8 (25.00%)	0 / 11 (0.00%)
occurrences (all)	3	2	0
Lymphocyte count decreased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Lipase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme abnormal			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
SARS-CoV-2 test negative			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vitamin D decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	3	0
Weight decreased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
White blood cell count decreased			
subjects affected / exposed	1 / 4 (25.00%)	1 / 8 (12.50%)	1 / 11 (9.09%)
occurrences (all)	1	1	1
Injury, poisoning and procedural complications			
Clavicle fracture			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Post procedural haematoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Radiation skin injury			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Transfusion reaction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vascular access complication			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Tricuspid valve disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

Supraventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 1	0 / 11 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Pericardial effusion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 1	0 / 11 (0.00%) 0
Mitral valve thickening subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Nervous system disorders			
Bell's palsy subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Drooling subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Neuralgia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Myoclonus subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 8 (12.50%) 1	1 / 11 (9.09%) 1
Febrile convulsion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 1	0 / 11 (0.00%) 0
Dysgeusia			

subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Peripheral motor neuropathy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Somnolence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	2	0	0
Transient ischaemic attack			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vlth nerve paralysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	2 / 4 (50.00%)	5 / 8 (62.50%)	1 / 11 (9.09%)
occurrences (all)	3	5	2
Anaemia			
subjects affected / exposed	3 / 4 (75.00%)	1 / 8 (12.50%)	3 / 11 (27.27%)
occurrences (all)	5	1	3
Iron deficiency anaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

Leukopenia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Lymphopenia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 8 (25.00%)	3 / 11 (27.27%)
occurrences (all)	0	2	3
Neutropenia			
subjects affected / exposed	2 / 4 (50.00%)	4 / 8 (50.00%)	0 / 11 (0.00%)
occurrences (all)	2	5	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
External ear inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Middle ear effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Eye oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Glaucoma			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Papilloedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Uveitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Retinopathy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Abdominal distension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Abdominal rigidity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Abdominal pain			
subjects affected / exposed	1 / 4 (25.00%)	1 / 8 (12.50%)	1 / 11 (9.09%)
occurrences (all)	1	1	1
Angular cheilitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

Ascites			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Dental caries			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Dental discomfort			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Diarrhoea			
subjects affected / exposed	3 / 4 (75.00%)	3 / 8 (37.50%)	2 / 11 (18.18%)
occurrences (all)	3	3	2
Dry mouth			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	1 / 11 (9.09%)
occurrences (all)	0	1	1
Dysphagia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	1 / 11 (9.09%)
occurrences (all)	0	2	1
Gingival bleeding			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Gastric ulcer			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

Intestinal stenosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Ileus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	3 / 4 (75.00%)	1 / 8 (12.50%)	2 / 11 (18.18%)
occurrences (all)	6	1	3
Odynophagia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Oesophagitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Rectal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Tooth loss			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	2 / 4 (50.00%)	1 / 8 (12.50%)	3 / 11 (27.27%)
occurrences (all)	3	1	3
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Hepatic cytolysis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	2	0
Hepatic vein thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Hyperbilirubinaemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Jaundice			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	2 / 4 (50.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	2	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	1 / 4 (25.00%)	2 / 8 (25.00%)	0 / 11 (0.00%)
occurrences (all)	1	3	0
Pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Prurigo			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Skin erosion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Nocturia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	2
Pollakiuria			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Urine flow decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Renal impairment			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Renal failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypopituitarism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal chest pain			

subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Muscular weakness			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	1 / 11 (9.09%)
occurrences (all)	0	1	1
Spinal pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Synovitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Temporomandibular pain and dysfunction syndrome			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Abdominal infection			

subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Bronchitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Bronchitis viral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	3	0
Gingivitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Folliculitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Cellulitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	1 / 11 (9.09%)
occurrences (all)	0	1	2
Candida infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Herpes ophthalmic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	1 / 11 (9.09%) 1
Influenza subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 3	0 / 11 (0.00%) 0
Oral fungal infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Oral viral infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Periodontitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Peritonsillar abscess subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 1	0 / 11 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Pneumocystis jirovecii pneumonia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Septic shock subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0

Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 1	0 / 11 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 5	0 / 11 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 2	0 / 11 (0.00%) 0
Tooth infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 1	0 / 11 (0.00%) 0
Soft tissue infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 1	0 / 11 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	1 / 11 (9.09%) 1
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Metabolism and nutrition disorders			
Cell death subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 8 (12.50%) 1	0 / 11 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	2 / 11 (18.18%) 2
Fluid retention subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 8 (0.00%) 0	0 / 11 (0.00%) 0
Dehydration			

subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hyperamylasaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypernatraemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Hypochloraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Hypomagnesaemia			

subjects affected / exposed	1 / 4 (25.00%)	1 / 8 (12.50%)	1 / 11 (9.09%)
occurrences (all)	1	1	1
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 8 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 4 (0.00%)	1 / 8 (12.50%)	0 / 11 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	Phase I 120 mg BID fasted	Phase I 150 mg BID fasted	Phase I 300 mg BID fasted
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 11 (100.00%)	8 / 8 (100.00%)	29 / 30 (96.67%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Tumour associated fever			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	1 / 11 (9.09%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	1	1	0
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Subclavian vein thrombosis			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Pallor			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Hypotension			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Venous thrombosis limb			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chronic fatigue syndrome			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	2 / 11 (18.18%)	2 / 8 (25.00%)	4 / 30 (13.33%)
occurrences (all)	2	2	6
Early satiety			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	4 / 11 (36.36%)	0 / 8 (0.00%)	5 / 30 (16.67%)
occurrences (all)	4	0	5
Gait disturbance			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hyperthermia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Mucosal inflammation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Non-cardiac chest pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Oedema peripheral			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	3 / 30 (10.00%)
occurrences (all)	1	0	3
Swelling			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	2	0	0
Supraclavicular fossa pain			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	3 / 11 (27.27%)	4 / 8 (50.00%)	5 / 30 (16.67%)
occurrences (all)	4	5	5
Peripheral swelling			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	1 / 30 (3.33%)
occurrences (all)	0	1	1
Swelling face			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Temperature regulation disorder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Xerosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Amenorrhoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Penile oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			

subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Aspiration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	1 / 11 (9.09%)	1 / 8 (12.50%)	3 / 30 (10.00%)
occurrences (all)	2	1	3
Dysphonia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Haemoptysis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	1	0	3
Dyspnoea			
subjects affected / exposed	1 / 11 (9.09%)	1 / 8 (12.50%)	2 / 30 (6.67%)
occurrences (all)	1	1	2
Hiccups			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			

subjects affected / exposed	2 / 11 (18.18%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	2	0	1
Pneumonitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Hypoxia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Lung infiltration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Pulmonary tumour thrombotic microangiopathy			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Depression			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Depressive symptom			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Fear of eating			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	1 / 30 (3.33%)
occurrences (all)	0	1	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 11 (9.09%)	1 / 8 (12.50%)	3 / 30 (10.00%)
occurrences (all)	1	1	3
Amylase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	2
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 11 (18.18%)	2 / 8 (25.00%)	4 / 30 (13.33%)
occurrences (all)	2	2	4
Blood albumin decreased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	1	0	3
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 11 (9.09%)	1 / 8 (12.50%)	4 / 30 (13.33%)
occurrences (all)	1	1	4
Blood bilirubin increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	1 / 30 (3.33%)
occurrences (all)	0	1	1
Blood magnesium decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	2
Blood lactate dehydrogenase increased			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	2 / 11 (18.18%)	1 / 8 (12.50%)	3 / 30 (10.00%)
occurrences (all)	2	1	4
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	2	0	1
Blood creatine increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Blood calcium decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Blood sodium increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
C-reactive protein increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	6 / 30 (20.00%)
occurrences (all)	0	1	8
Protein total decreased			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	2
Platelet count decreased			
subjects affected / exposed	0 / 11 (0.00%)	4 / 8 (50.00%)	5 / 30 (16.67%)
occurrences (all)	0	5	6
Neutrophil count decreased			
subjects affected / exposed	1 / 11 (9.09%)	1 / 8 (12.50%)	2 / 30 (6.67%)
occurrences (all)	1	3	2
Lymphocyte count decreased			
subjects affected / exposed	2 / 11 (18.18%)	1 / 8 (12.50%)	3 / 30 (10.00%)
occurrences (all)	2	1	3
Lipase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	3 / 30 (10.00%)
occurrences (all)	0	1	5
Hepatic enzyme abnormal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
SARS-CoV-2 test negative			
subjects affected / exposed	1 / 11 (9.09%)	2 / 8 (25.00%)	0 / 30 (0.00%)
occurrences (all)	2	4	0
Vitamin D decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	5 / 30 (16.67%)
occurrences (all)	1	0	5
White blood cell count decreased			
subjects affected / exposed	2 / 11 (18.18%)	1 / 8 (12.50%)	5 / 30 (16.67%)
occurrences (all)	4	1	6
Injury, poisoning and procedural complications			
Clavicle fracture			

subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Fall			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Post procedural haematoma			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Radiation skin injury			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Transfusion reaction			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Skin laceration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Vascular access complication			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Tricuspid valve disease			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	2	0	0

Supraventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Pericardial effusion subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Mitral valve thickening subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Nervous system disorders			
Bell's palsy subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	1 / 30 (3.33%) 1
Drooling subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Neuralgia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Myoclonus subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 3	0 / 8 (0.00%) 0	2 / 30 (6.67%) 2
Febrile convulsion subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Dysgeusia			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	3
Neuropathy peripheral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Peripheral motor neuropathy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	1 / 11 (9.09%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	1	1	0
Taste disorder			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Transient ischaemic attack			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Vlth nerve paralysis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	3 / 11 (27.27%)	1 / 8 (12.50%)	6 / 30 (20.00%)
occurrences (all)	16	1	10
Anaemia			
subjects affected / exposed	4 / 11 (36.36%)	0 / 8 (0.00%)	15 / 30 (50.00%)
occurrences (all)	9	0	19
Iron deficiency anaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0

Leukopenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Lymphopenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	6 / 30 (20.00%)
occurrences (all)	9	0	14
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
External ear inflammation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Hypoacusis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Middle ear effusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Dry eye			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Eye oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Glaucoma			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Papilloedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Uveitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Retinopathy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Abdominal rigidity			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	1	0	1
Abdominal pain			
subjects affected / exposed	2 / 11 (18.18%)	0 / 8 (0.00%)	3 / 30 (10.00%)
occurrences (all)	3	0	3
Angular cheilitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0

Ascites			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	2 / 11 (18.18%)	0 / 8 (0.00%)	4 / 30 (13.33%)
occurrences (all)	2	0	6
Dental caries			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Dental discomfort			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	2 / 11 (18.18%)	3 / 8 (37.50%)	12 / 30 (40.00%)
occurrences (all)	2	4	16
Dry mouth			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Dysphagia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Gingival bleeding			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	3 / 30 (10.00%)
occurrences (all)	1	0	3
Gastric ulcer			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Haemorrhoids			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1

Intestinal stenosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Ileus			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	3 / 11 (27.27%)	3 / 8 (37.50%)	11 / 30 (36.67%)
occurrences (all)	3	5	12
Odynophagia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Stomatitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	1	0	1
Tooth loss			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Toothache			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	2 / 11 (18.18%)	0 / 8 (0.00%)	10 / 30 (33.33%)
occurrences (all)	3	0	11
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hepatic cytolysis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hepatic vein thrombosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Jaundice			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	3 / 11 (27.27%)	0 / 8 (0.00%)	3 / 30 (10.00%)
occurrences (all)	3	0	5
Dermatitis allergic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Eczema			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	3	0	0
Erythema			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Hyperhidrosis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Night sweats			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	1	0	1

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	3 / 11 (27.27%)	1 / 8 (12.50%)	3 / 30 (10.00%)
occurrences (all)	3	1	3
Pruritus			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	1	0	2
Prurigo			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Skin erosion			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Skin exfoliation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	3 / 30 (10.00%)
occurrences (all)	1	0	3
Nocturia			

subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Haematuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Urine flow decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Renal impairment			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Renal failure			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Hypopituitarism			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Back pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	1	0	2
Musculoskeletal chest pain			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Groin pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	1	0	1
Spinal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Synovitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Temporomandibular pain and dysfunction syndrome			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Abdominal infection			

subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Bronchitis viral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	1 / 11 (9.09%)	1 / 8 (12.50%)	1 / 30 (3.33%)
occurrences (all)	1	1	1
Gingivitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
Ear infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Candida infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Herpes ophthalmic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0

Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Influenza subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 8 (12.50%) 1	0 / 30 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Oral fungal infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Oral viral infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Periodontitis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Peritonsillar abscess subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 2	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Pneumocystis jirovecii pneumonia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Septic shock subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0

Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 8 (12.50%) 1	1 / 30 (3.33%) 1
Sinusitis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Tooth infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	1 / 30 (3.33%) 1
Soft tissue infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	2 / 30 (6.67%) 2
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Metabolism and nutrition disorders			
Cell death subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 8 (0.00%) 0	0 / 30 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	4 / 11 (36.36%) 4	1 / 8 (12.50%) 1	9 / 30 (30.00%) 11
Fluid retention subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 8 (0.00%) 0	1 / 30 (3.33%) 1
Dehydration			

subjects affected / exposed	3 / 11 (27.27%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	3	0	3
Hyperamylasaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Hypercholesterolaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Hypercalcaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	1	0	2
Hyperkalaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hypernatraemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hypochloraemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 8 (12.50%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Hypocalcaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Hypoalbuminaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Hypoglycaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	3 / 11 (27.27%)	2 / 8 (25.00%)	6 / 30 (20.00%)
occurrences (all)	4	4	6
Hypomagnesaemia			

subjects affected / exposed	1 / 11 (9.09%)	3 / 8 (37.50%)	3 / 30 (10.00%)
occurrences (all)	1	4	3
Hyponatraemia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 8 (12.50%)	2 / 30 (6.67%)
occurrences (all)	1	1	2
Hypophosphataemia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 8 (25.00%)	3 / 30 (10.00%)
occurrences (all)	0	2	3
Vitamin D deficiency			
subjects affected / exposed	0 / 11 (0.00%)	0 / 8 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Phase I 160 mg QD fasted	Phase I 120 mg QD fasted	Phase I 80 mg QD fasted
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 5 (100.00%)	8 / 8 (100.00%)	8 / 8 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tumour associated fever			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Subclavian vein thrombosis			

subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Peripheral coldness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pallor			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Venous thrombosis limb			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chronic fatigue syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Asthenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Early satiety			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	1 / 5 (20.00%)	2 / 8 (25.00%)	2 / 8 (25.00%)
occurrences (all)	1	2	2
Gait disturbance			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyperthermia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Localised oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Oedema			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Influenza like illness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Swelling			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Supraclavicular fossa pain			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 5 (0.00%)	2 / 8 (25.00%)	0 / 8 (0.00%)
occurrences (all)	0	4	0
Peripheral swelling			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Swelling face			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Temperature regulation disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Xerosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Amenorrhoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Penile oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Aspiration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Dysphonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Hiccups			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Pneumonitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Lung infiltration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Pulmonary embolism			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pulmonary tumour thrombotic microangiopathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Respiratory failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Depression			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Depressive symptom			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Fear of eating			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	1 / 5 (20.00%)	2 / 8 (25.00%)	0 / 8 (0.00%)
occurrences (all)	1	2	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Amylase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	2
Blood albumin decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Blood bilirubin increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 5 (0.00%)	2 / 8 (25.00%)	2 / 8 (25.00%)
occurrences (all)	0	2	2
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Blood creatine increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Blood calcium decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood sodium increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Protein total decreased			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Lymphocyte count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Lipase increased			
subjects affected / exposed	2 / 5 (40.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Hepatic enzyme abnormal			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
SARS-CoV-2 test negative			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vitamin D decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
White blood cell count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Clavicle fracture			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Post procedural haematoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Radiation skin injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Transfusion reaction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vascular access complication			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Tricuspid valve disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	1 / 8 (12.50%)
occurrences (all)	0	1	1

Supraventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Pericardial effusion subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Mitral valve thickening subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	1 / 8 (12.50%) 1
Nervous system disorders			
Bell's palsy subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	1 / 8 (12.50%) 1
Drooling subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Neuralgia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Myoclonus subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 8 (25.00%) 3	0 / 8 (0.00%) 0
Febrile convulsion subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Dysgeusia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Peripheral motor neuropathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Transient ischaemic attack			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vlth nerve paralysis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Anaemia			
subjects affected / exposed	1 / 5 (20.00%)	2 / 8 (25.00%)	1 / 8 (12.50%)
occurrences (all)	1	2	1
Iron deficiency anaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Leukopenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
External ear inflammation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Middle ear effusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Glaucoma			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Papilloedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Vision blurred			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Uveitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Retinopathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal rigidity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Abdominal pain upper			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	2 / 5 (40.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	2	0	1
Angular cheilitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Ascites			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Dental caries			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dental discomfort			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	1 / 5 (20.00%)	1 / 8 (12.50%)	1 / 8 (12.50%)
occurrences (all)	1	1	1
Dry mouth			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Dysphagia			
subjects affected / exposed	0 / 5 (0.00%)	2 / 8 (25.00%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
Gingival bleeding			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Intestinal stenosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Ileus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	3 / 5 (60.00%)	1 / 8 (12.50%)	1 / 8 (12.50%)
occurrences (all)	3	2	1
Odynophagia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tooth loss			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 5 (20.00%)	2 / 8 (25.00%)	1 / 8 (12.50%)
occurrences (all)	1	2	1
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hepatic cytolysis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hepatic vein thrombosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Jaundice			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Dermatitis allergic			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Eczema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Hyperhidrosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Prurigo			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Rash papular			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Skin erosion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nocturia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	2 / 5 (40.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	2	0	1
Pollakiuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Urine flow decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Renal impairment			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Renal failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypopituitarism			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Back pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal chest pain			

subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Muscular weakness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Groin pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Spinal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Synovitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Temporomandibular pain and dysfunction syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Abdominal infection			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Bronchitis viral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Folliculitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Candida infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Herpes ophthalmic			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Influenza subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 8 (12.50%) 1	0 / 8 (0.00%) 0
Oral fungal infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Oral viral infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 8 (12.50%) 1	0 / 8 (0.00%) 0
Periodontitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Peritonsillar abscess subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Pneumocystis jirovecii pneumonia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Septic shock subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0

Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	1 / 8 (12.50%) 1
Tooth infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Soft tissue infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 8 (12.50%) 1	0 / 8 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 8 (0.00%) 0	1 / 8 (12.50%) 2
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Metabolism and nutrition disorders			
Cell death subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 2	0 / 8 (0.00%) 0	3 / 8 (37.50%) 3
Fluid retention subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 8 (12.50%) 1	0 / 8 (0.00%) 0
Dehydration			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyperamylasaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	1 / 5 (20.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	2	2	0
Hyperkalaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypernatraemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypochloraemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	2
Hypoglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
Hypomagnesaemia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 8 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Hypophosphataemia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 8 (12.50%)	2 / 8 (25.00%)
occurrences (all)	0	3	2
Vitamin D deficiency			
subjects affected / exposed	0 / 5 (0.00%)	0 / 8 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Phase I 300 mg QD fasted		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Tumour associated fever			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Tumour haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Subclavian vein thrombosis			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Peripheral coldness			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pallor			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypotension			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Venous thrombosis limb			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Chronic fatigue syndrome			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Chills			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Asthenia			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Early satiety			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Gait disturbance			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
General physical health deterioration			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hyperthermia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Face oedema			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Facial pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Localised oedema			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Malaise			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Mucosal inflammation			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Non-cardiac chest pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Oedema			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Influenza like illness			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Oedema peripheral			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Swelling			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Supraclavicular fossa pain			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Peripheral swelling			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Swelling face			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Temperature regulation disorder			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Xerosis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
Amenorrhoea			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pelvic pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Penile oedema			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Vaginal haemorrhage			

subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Aspiration			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Dysphonia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Haemoptysis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Hiccups			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Nasal congestion			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pleural effusion			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pneumonitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypoxia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Lung infiltration			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Productive cough			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pulmonary embolism			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pulmonary tumour thrombotic microangiopathy			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Wheezing			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Depression			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Depressive symptom			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Fear of eating			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Insomnia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Amylase increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood albumin decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood magnesium decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood lactate dehydrogenase increased			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood creatinine increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood creatine increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood calcium decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood phosphorus decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood sodium increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood uric acid increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
C-reactive protein increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Protein total decreased			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Platelet count decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Neutrophil count decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Lymphocyte count decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Lipase increased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hepatic enzyme abnormal			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
SARS-CoV-2 test negative			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Vitamin D decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Clavicle fracture			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Contusion			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Eye contusion			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Fall			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Post procedural haematoma			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Procedural pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Radiation skin injury			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Transfusion reaction			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Skin laceration			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Vascular access complication			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Tricuspid valve disease			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		

Supraventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Pericardial effusion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Mitral valve thickening subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Nervous system disorders			
Bell's palsy subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Dizziness subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Drizzling subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Neuralgia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Myoclonus subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Headache subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Febrile convulsion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Dysgeusia			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Neuropathy peripheral			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Peripheral motor neuropathy			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Sciatica			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Presyncope			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Somnolence			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Taste disorder			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Transient ischaemic attack			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Vlth nerve paralysis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	2 / 4 (50.00%)		
occurrences (all)	4		
Anaemia			
subjects affected / exposed	2 / 4 (50.00%)		
occurrences (all)	4		
Iron deficiency anaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		

Leukopenia			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Lymphopenia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	3 / 4 (75.00%)		
occurrences (all)	5		
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
External ear inflammation			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypoacusis			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Middle ear effusion			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Vertigo			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Dry eye			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Eye oedema			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Glaucoma			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Papilloedema			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Vision blurred			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Uveitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Retinopathy			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Periorbital oedema			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Abdominal distension			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Abdominal rigidity			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Angular cheilitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		

Ascites			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Dental caries			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Dental discomfort			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	2		
Dry mouth			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Dysphagia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Gingival bleeding			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Gastric ulcer			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Haemorrhoids			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		

Intestinal stenosis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Inguinal hernia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Ileus			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Odynophagia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Oesophagitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Rectal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Stomatitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Tooth loss			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hepatic cytolysis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hepatic vein thrombosis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hyperbilirubinaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Jaundice			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Dermatitis allergic			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Eczema			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hyperhidrosis			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Night sweats			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Petechiae			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Prurigo			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Rash papular			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Rash pruritic			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Skin erosion			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Skin exfoliation			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Nocturia			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Haematuria			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pollakiuria			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Urine flow decreased			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Renal impairment			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Renal failure			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypopituitarism			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Hypothyroidism			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Back pain			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Musculoskeletal chest pain			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Muscular weakness			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Groin pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Bone pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Spinal pain			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Synovitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Temporomandibular pain and dysfunction syndrome			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Abdominal infection			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Bronchitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Bronchitis viral			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
COVID-19			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Gingivitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Gastroenteritis viral			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Folliculitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Ear infection			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Candida infection			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Herpes ophthalmic			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		

Lower respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Oral candidiasis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Oral fungal infection			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Oral viral infection			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Periodontitis			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Peritonsillar abscess			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pharyngitis			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Septic shock			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		

Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Sinusitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Tooth infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Soft tissue infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Metabolism and nutrition disorders			
Cell death subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Decreased appetite subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Fluid retention subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Dehydration			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hyperamylasaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypercholesterolaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hyperkalaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypernatraemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypochloraemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypocalcaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypoalbuminaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypoglycaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypomagnesaemia			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hypophosphataemia			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Vitamin D deficiency			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 July 2016	<ul style="list-style-type: none">• To modify the inclusion criteria to include only participants who had exhausted all options and for whom no standard therapy exists.• To update the DLT criteria for gastrointestinal toxicity and thrombocytopenia toxicity.
31 August 2017	The primary purpose of this amendment was to specify the clinical indications to be enrolled in this study.
27 June 2018	<p>The primary purpose of this amendment was to add clinical indications to be investigated in the Phase II part. In addition, several study assessments have been modified in this amendment:</p> <ul style="list-style-type: none">• The PBMC sample collection for the evaluation of H3K27 methylations has been modified to a whole blood sample collection.• The required use of highly effective birth control for women of child bearing potential has been modified from 28D to during study follow-up to be consistent with the updated IB.
10 August 2021	The main purpose of this amendment was to add an exploratory PD marker. To facilitate this measurement, additional whole blood samples were collected in MAK683-treated participants.
16 March 2023	The main purpose of this amendment was to modify the study conduct following the enrollment halt that came into effect on 08-Nov-2022, by reducing the assessment burden and minimizing data collection in ongoing trial subjects. The definition of end of study was revised to include the option for participants still on study treatment and who, in the opinion of the investigator, are still deriving clinical benefit at the time of end of study, to transfer to another study or to use an alternative way to provide study treatment to these participants. Furthermore, use of live vaccines was added as one of the prohibited concomitant therapies.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported